Loading
Latest filing published 29 Apr 2026 for Compass Therapeutics, Inc., €40k. Read the official filing
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jonathan Anderman is a declared insider of Compass Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 7 April 2025 to 29 April 2026, the count stands at 4 filings.
The open-market record is one-sided, with 2 purchases worth €69k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants. Since January 2026: 1 purchase and no sales on the market.
The newest entry dates from 30 April 2026: an open-market purchase of €40k, in Compass Therapeutics, Inc. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations